Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 1/20 | 0.56 |
| ▸ | ESR1 | P03372 | 2/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.56 |
| ▸ | LTA4H | P09960 | 2/20 | 0.54 |
| ▸ | KIF11 | P52732 | 7/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25048 | 1.00 | CA4 (0.56) | CA4ESR1ESR2LTA4HKIF11 | |
| SCHEMBL12459850 | 0.92 | ACHE (0.58) | CA4ESR1ESR2LTA4HKIF11 | |
| SCHEMBL3098811 | 0.91 | CA1 (0.61) | CA4LTA4HCA12CA1CA2 | |
| SCHEMBL24258459 | 0.90 | ESR1 (0.47) | CA4ESR1ESR2LTA4HKIF11 | |
| SCHEMBL16591527 | 0.90 | ESR2 (0.74) | CA4ESR1ESR2LTA4HKIF11 | |
| SCHEMBL20878780 | 0.90 | ESR1 (0.47) | CA4ESR1ESR2LTA4HKIF11 | |
| SCHEMBL18127940 | 0.87 | CA4 (0.52) | CA4ESR1ESR2LTA4HKIF11 | |
| SCHEMBL2689280 | 0.86 | CA4 (0.56) | CA4ESR1ESR2LTA4HKIF11 | |
| SCHEMBL15628358 | 0.86 | KIF11 (0.43) | CA4ESR1ESR2LTA4HKIF11 | |
| SCHEMBL13054813 | 0.86 | KIF11 (0.46) | CA4ESR1ESR2LTA4HKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2906246-B1 | VEGF NEUTRALIZING PRODRUGS COMPRISING RANIBIZUMAB FOR THE TREATMENT OF OCULAR CONDITIONS CHARACTERIZED BY OCULAR NEOVASCULARIZATION | ASCENDIS PHARMA OPHTHALMOLOGY DIV A/S (DK) | 2023-07-26 | — | — | EP | disclosed |
| US-20220389428-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE COMPRISING THE SAME, AND PREPARATION METHOD AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2022-12-08 | — | — | US | disclosed |
| EP-3862024-A1 | SIRNA CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2021-08-11 | — | — | EP | disclosed |
| US-20210206809-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | VERA THERAPEUTICS INC (US) | 2021-07-08 | — | — | US | disclosed |
| EP-3842534-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2021-06-30 | — | — | EP | disclosed |
| US-20210130379-A1 | SYNTHESIS OF FMOC-PROTECTED MORPHOLINO MONOMERS AND THEIR USE IN THE SYNTHESIS OF MORPHOLINO OLIGOMER | INDIAN ASSOCIATION FOR THE CULTIVATION OF SCIENCE (IN) | 2021-05-06 | — | — | US | disclosed |
| EP-3030244-B1 | POLYCONJUGATES FOR DELIVERY OF RNAI TRIGGERS TO TUMOR CELLS IN VIVO | ARROWHEAD PHARMACEUTICALS INC (US) | 2021-04-21 | — | — | EP | disclosed |
| US-10968196-B2 | Substituted β-lapachones for treating cancer | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-04-06 | — | — | US | disclosed |
| EP-3719127-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, PREPARATION METHOD, AND USE | Suzhou Ribo Life Science Co., Ltd. (CN) | 2020-10-07 | — | — | EP | disclosed |
| EP-3718572-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, PREPARATION METHOD AND USE | Suzhou Ribo Life Science Co., Ltd. (CN) | 2020-10-07 | — | — | EP | disclosed |
| US-20090111756-A1 | Monomethylvaline Compounds Having Phenylalanine Carboxy Modifications at the C-Terminus | SEATTLE GENECTICS, INC. (US) | 2009-04-30 | — | — | US | disclosed |
| EP-0649429-B1 | HETEROATOMIC OLIGONUCLEOSIDE LINKAGES | ISIS PHARMACEUTICALS INC (US) | 2008-08-27 | — | — | EP | disclosed |
| US-7388002-B2 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-20080004234-A1 | System for delivering therapeutic agents into living cells and cells nuclei | SEGEV LABORATORIES LIMITED (IL) | 2008-01-03 | — | — | US | disclosed |
| US-20080004234-A1 | System for delivering therapeutic agents into living cells and cells nuclei | SEGEV LABORATORIES LIMITED (IL) | 2008-01-03 | — | — | US | disclosed |
| US-20070072909-A1 | deblocking, deprotecting; debenzylation; for preventing pain, diarrhea | EURO-CELTIQUE S.A. | 2007-03-29 | — | — | US | disclosed |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS (US) | 2007-03-08 | — | — | US | disclosed |
| EP-0703498-B1 | Photosensitive resin composition and method for forming a photoresist pattern | MITSUBISHI CHEM CORP (JP) | 1997-12-29 | — | — | EP | disclosed |
| US-5698362-A | CONTAINING A TRIARYLMETHANE DERIVATIVE; HIGH RESOLUTION, EXCELLENT IN DEPTH OF FOCUS AND PATTERN PROFILE, STORAGE STABLE | MITSUBISHI CHEMICAL CORPORATION (JP) | 1997-12-16 | — | — | US | disclosed |
| EP-0703498-A1 | Photosensitive resin composition and method for forming a photoresist pattern | MITSUBISHI CHEMICAL CORPORATION (JP) | 1996-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111756-A1 | Monomethylvaline Compounds Having Phenylalanine Carboxy Modifications at the C-Terminus | MMAB, PTMS, CAD | CA4 1185/4885ESR1 3998/4885ESR2 4569/4885 |
| US-10968196-B2 | Substituted β-lapachones for treating cancer | NLN, NDUFB7, NDUFB5 | CA4 2899/4885ESR1 2357/4885ESR2 1387/4885 |
| US-20210130379-A1 | SYNTHESIS OF FMOC-PROTECTED MORPHOLINO MONOMERS AND THEIR USE IN THE SYNTHESIS OF MORPHOLINO OLIGOMER | NONO, MPHOSPH6, PMM2 | CA4 3058/4885ESR1 4450/4885ESR2 4575/4885 |
| US-20220389428-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE COMPRISING THE SAME, AND PREPARATION METHOD AND USE THEREOF | NSUN2, RNGTT, ADAR | CA4 4409/4885ESR1 2534/4885ESR2 4183/4885 |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | DERA, NT5C3B, DUT | CA4 3164/4885ESR1 664/4885ESR2 929/4885 |
| US-20210206809-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | AGO2, TARBP1, TPR | CA4 905/4885ESR1 1688/4885ESR2 1334/4885 |
| US-20070072909-A1 | deblocking, deprotecting; debenzylation; for preventing pain, diarrhea | OPRL1, DECR1, PKD1 | CA4 2681/4885ESR1 3415/4885ESR2 1934/4885 |
| US-20080004234-A1 | System for delivering therapeutic agents into living cells and cells nuclei | RCC1, NUMA1, ACIN1 | CA4 3870/4885ESR1 882/4885ESR2 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.